Former Sandoz Inc. CEO Don DeGolyer Leads PharmaTech Startup Ategenos as Company Prepares Public Launch

Key Takeaways:

• Former Sandoz Inc. CEO Don DeGolyer has co-founded Ategenos.
• Ategenos is a PharmaTech startup preparing for a public launch.
• The company aims to address the $1 trillion global issue of medication non-adherence.
• Medication non-adherence is a significant crisis in healthcare.
• Experienced leadership is driving Ategenos’ mission to improve adherence.

Veteran Pharma Leader Launches New Venture

Don DeGolyer, the former CEO of Sandoz Inc. and a seasoned pharmaceutical operator, has co-founded a new PharmaTech startup named Ategenos. The company is preparing for its public launch as it sets out to address a pressing issue in healthcare.

Tackling a $1 Trillion Crisis

Ategenos aims to confront the global crisis of medication non-adherence, a problem that costs the healthcare industry $1 trillion worldwide. Medication non-adherence refers to patients not taking their medications as prescribed, leading to poor health outcomes and increased medical costs.

Preparing for Public Launch

As Ategenos readies for its public debut, the company is positioned to bring innovative solutions to the market under the leadership of DeGolyer. With his extensive experience in the pharmaceutical industry, DeGolyer’s guidance is anticipated to steer the company towards making a significant impact on medication adherence.

Leadership with Proven Expertise

DeGolyer’s tenure at Sandoz Inc., along with his reputation as a veteran pharma operator, underscores the expertise behind Ategenos. His involvement signals a strong commitment to addressing the challenges associated with medication non-adherence on a global scale.

Addressing a Global Healthcare Challenge

Medication non-adherence remains one of the most significant yet under-recognized issues in healthcare. By focusing on this $1 trillion problem, Ategenos seeks to improve patient outcomes and reduce unnecessary healthcare expenditures. The company’s upcoming public launch marks a critical step in bringing attention and solutions to this pervasive issue.